Evolus (EOLS) is presented as a top pick, considered the cheapest high-growth stock in the beauty sector with revenue growing at 32%. Its core product is a disruptor to Botox, and the upcoming launch of a facial filler line provides a significant catalyst for future growth. Another high-conviction opportunity is e.l.f. Beauty (ELF), which has proven its resilience and strong pricing power. ELF's position as the #1 brand among Gen Z and Gen Alpha consumers provides a strong, long-term growth runway. Other names like InMode (INMD) and Olaplex (OLPX) face significant headwinds and are best avoided for now.

e.l.f. Beauty (ELF)

• The speaker is bullish on ELF and holds a position in the stock.
• The stock price previously dropped to $49 due to fears of high tariffs on Chinese goods, as 80% of its products are made in China.
• The actual average tariff ended up being 51%, significantly lower than the feared 128%, which the speaker notes is "not a company extinction event."
• ELF successfully managed the tariff impact by raising prices by $1 across its product line, a move that was well-received by consumers without backlash.
• The company operates with a very high gross margin of 71%, selling low-cost makeup.
• It is positioned as a disruptor to legacy brands like L'Oreal by offering high-quality products at a lower price point.
• ELF is the #1 brand among Gen Z and Gen Alpha, indicating strong brand power with younger demographics.

Takeaways

• ELF has demonstrated resilience in the face of supply chain challenges and has strong pricing power.
• Its popularity with younger consumers provides a long-term growth runway.
• For investors looking for a growth stock in the beauty sector with proven brand strength and high profitability, ELF presents a compelling case.

Oddity Tech (ODD)

• The speaker is bullish on the company's fundamentals but is not currently adding to their position because the stock "went up 80% too quick."
• Its primary brand, Il Makiage, uses AI to create custom-matched foundation, is sold direct-to-consumer, and is on track to become a $1 billion brand.
• The company has a multi-brand strategy, with a second brand, Spoiled Child, and a third brand (a telehealth platform for skin/body care) launching soon. A fourth brand is also in development.
• Financial Health:
  • Price-to-Sales ratio: 4.4 (considered "not that expensive").
  • Gross Margin: 73% (very high).
  • EBITDA Margin: Close to 20%.
  • Rule of 40: Achieves a score of 44, indicating a healthy balance of growth and profitability.
  • Valuation: Considered cheap based on an "EV over GP over RG" metric of 0.3.

Takeaways

• ODD is a technology-driven beauty company with a successful model for creating and scaling direct-to-consumer brands.
• The upcoming launch of its third and fourth brands are potential catalysts for future growth.
• While the business is strong, the stock has had a significant run-up. Investors might consider waiting for a more attractive entry point before starting a position.

InMode (INMD)

• The speaker is currently neutral-to-bearish on INMD and no longer owns the stock.
• InMode sells medical devices (costing around $100,000 each) for semi-invasive fat reduction procedures.
• The core business of selling these machines has stalled due to high interest rates, which have pushed financing costs for doctors to 14-15%.
• Revenue growth is currently negative at -6%.
• The company is currently sustained by its profitable consumables business (the tips and needles used in procedures), which has an EBITDA margin of 28%. This is compared to a "printer and cartridge" business model.
• The speaker views this as a "stocks for rate cuts" company, meaning its fortunes could reverse if and when interest rates decline.

Takeaways

• INMD's growth is highly dependent on the macroeconomic environment, specifically interest rates.
• The profitable consumables business provides a stable cash flow stream, but the lack of growth in machine sales is a major headwind.
• This stock may appeal to investors who are betting on future interest rate cuts, but it is not attractive based on its current growth trajectory.

AirSculpt (AIRS)

• The speaker is not interested in AIRS at the moment.
• It is seen as a direct, head-to-head competitor to InMode, offering a very similar fat-reduction product.
• Like InMode, the business is struggling because the high cost of its machines is a deterrent for buyers in the current high-interest-rate environment.
• The speaker believes the company could see a comeback with lower interest rates and improved consumer confidence, but states, "we are not there yet."

Takeaways

• AIRS faces the same macroeconomic headwinds as its competitor, InMode.
• Given the lack of current growth and intense competition, this is a "wait and see" stock for most investors.

Olaplex (OLPX)

• The speaker is bearish on OLPX.
• The business is described as a "shampoo business" focused on a niche market of hair repair, which the speaker feels is "too specific."
• A major risk is the intense competition from consumer goods giants with massive marketing budgets. While Olaplex has patents, defending them against larger players could be extremely expensive.
• The company's revenue is declining, which is a significant red flag.
• Although the stock is up 50% from its recent lows, the speaker suspects this is a short-term rebound rather than a fundamental recovery.

Takeaways

• Declining revenue is a major concern that overshadows the company's decent 25% EBITDA margin.
• The competitive landscape is a significant long-term risk. Investors should be cautious and not mistake a short-term price bounce for a sustainable turnaround.

The Honest Company (HNST)

• The speaker is bearish on HNST, stating the "numbers don't look attractive."
• Financial performance is weak:
  • EBITDA margin is only 1%.
  • Revenue growth is 7%, which is not considered high enough.
• The company's main product focus is on baby items, with beauty being a smaller segment.
• Its key differentiator of being "cruelty-free" and "clean" is no longer unique, as many brands now occupy this space.

Takeaways

• With weak profitability and slow growth, the company's financial fundamentals are not compelling.
• The brand's competitive edge has likely diminished over time. This is not presented as an attractive investment opportunity.

Evolus (EOLS)

• The speaker is very bullish on EOLS, calling it "very interesting" and the cheapest, high-growth stock among the beauty names analyzed.
• Evolus operates in the medical aesthetics space, which is all cash-pay and requires FDA approval, creating a barrier to entry.
• Its main product, Jeuveau, is an anti-wrinkle injection positioned as a direct competitor and disruptor to Botox. It is growing revenue at 32% per year.
• The company is launching a new line of facial fillers (Evolus Sculpt, Evolus Lips), which has strong synergy with its existing business. The speaker notes that 70% of patients who get injections also get fillers.
• Valuation is very attractive:
  • Trading at less than 2x forward revenue.
  • Trading at less than 3x forward gross profit.
  • Gross Profit Margin: 68%.
• The low 1% EBITDA margin is attributed to high R&D and marketing expenses for its new product launch, which the speaker views as a strategic reinvestment in the business rather than a sign of poor profitability.

Takeaways

• EOLS is presented as a high-growth, undervalued disruptor in the lucrative medical aesthetics market.
• The rapid growth of its core product and the upcoming launch of a synergistic filler product line are major potential catalysts.
• For investors seeking exposure to the beauty/aesthetics sector, EOLS appears to be a compelling opportunity due to its high growth rate and cheap valuation.